D-0106-2025 Class II Ongoing
FDA drug recall D-0106-2025 was initiated by Rising Pharma Holding, Inc. on Nov 19, 2024 and is designated Class II. Reason for recall: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit The recall status is ongoing. Affected quantity: 122,925 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 11, 2024
- Initiation Date
- Nov 19, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 122,925 bottles
Product description
Duloxetine Delayed-Release Capsules USP, 30 mg, a) 30 count (NDC 57237-018-30), b) 90 count (NDC 57237-018-90) and c) 1000 count (NDC 57237-018-99) bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ
Reason for recall
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit
Distribution pattern
Nationwide.
Code information
a) 30s; DT3023019A, exp. date Jan-25 DT3023050A, exp. date Apr-25; b) 90s; DT3023022A, exp. date Jan-25; c) 1000s; DT3022108A, DT3022107A, DT3022106A, DT3022111A, DT3022109A, exp. date Nov-24, DT3023001A, DT3023003A, exp. date Dec-24, DT3023024A, DT3023020B, exp. date Jan-25 DT3023027A, DT3023028A, exp. date Feb-25, DT3023034A, exp. date Mar-25, DT3023049A, exp. date Apr-25, DT3023095A, exp. date Jul-25
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0106-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026